Royce & Associates LP Purchases New Holdings in TELA Bio, Inc. (NASDAQ:TELA)

Royce & Associates LP purchased a new stake in shares of TELA Bio, Inc. (NASDAQ:TELA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,000,064 shares of the company’s stock, valued at approximately $3,020,000. Royce & Associates LP owned about 2.54% of TELA Bio at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Commonwealth Equity Services LLC grew its holdings in TELA Bio by 91.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,441 shares of the company’s stock valued at $86,000 after purchasing an additional 13,555 shares during the period. GSA Capital Partners LLP grew its holdings in TELA Bio by 398.8% during the third quarter. GSA Capital Partners LLP now owns 112,205 shares of the company’s stock valued at $284,000 after purchasing an additional 89,712 shares during the period. Landscape Capital Management L.L.C. bought a new position in TELA Bio during the third quarter valued at $362,000. Finally, Stonepine Capital Management LLC grew its holdings in TELA Bio by 77.4% during the third quarter. Stonepine Capital Management LLC now owns 1,110,000 shares of the company’s stock valued at $2,808,000 after purchasing an additional 484,355 shares during the period. 94.35% of the stock is owned by hedge funds and other institutional investors.

TELA Bio Price Performance

TELA Bio stock opened at $2.36 on Thursday. TELA Bio, Inc. has a one year low of $2.18 and a one year high of $6.50. The business has a fifty day moving average price of $2.60 and a 200-day moving average price of $2.71. The company has a debt-to-equity ratio of 14.22, a current ratio of 2.62 and a quick ratio of 1.81. The firm has a market capitalization of $92.96 million, a P/E ratio of -1.40 and a beta of 1.10.

TELA Bio Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.